Device Watchman_ic

Watchman Access System

Payments companies reported to CMS as associated with Watchman Access System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$8.6Massociated payments (2023-2025)
16,954clinicians with associated payments
1company reporting

By year

2023 $3.3M
2024 $2.7M
2025 $2.5M

Payments reported as associated with Watchman Access System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Cardiovascular Disease $2.5M
Clinical Cardiac Electrophysiology $2.3M
Interventional Cardiology $1.7M
Family $276K
Neurology (Psychiatry & Neurology) $255K
Physician Assistant $197K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Watchman Access System

These are the largest totals companies reported as associated with Watchman Access System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Steven Filby Pinehurst, NC Interventional Cardiology $263,897.30
Shephal Doshi Santa Monica, CA Clinical Cardiac Electrophysiology $233,564.89
Rahul Bhardwaj Loma Linda, CA Clinical Cardiac Electrophysiology $204,997.95
David Rose Tampa, FL Neurology (Psychiatry & Neurology) $157,534.77
Jorge Romero Syracuse, NY Clinical Cardiac Electrophysiology $113,955.33
Oluseun Alli Charlotte, NC Interventional Cardiology $113,839.55
Sanjay Maniar Houston, TX Cardiovascular Disease $110,980.03
George Jabbour Altoona, PA Cardiovascular Disease $110,499.50
Ashish Gupta Phoenix, AZ Cardiovascular Disease $102,825.35
Bryon Gentile II Worcester, MA Cardiovascular Disease $101,085.14

Prescribed Watchman Access System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.